Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ANI Pharmaceuticals acquires two NDAs from Merck for $75m
The acquisition was funded through cash on hand. The assets were acquired from a Dutch subsidiary of Merck by ANI Pharmaceuticals C.V., a Netherlands based wholly owned indirect
The acquisition was funded through cash on hand. The assets were acquired from a Dutch subsidiary of Merck by ANI Pharmaceuticals C.V., a Netherlands based wholly owned indirect
The trial is evaluating the use of Pexa-Vec to treat HCC patients who have failed locoregional therapies and are eligible for treatment with sorafenib (Nexavar), the only approved
UPTRAVI is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness was
cCK18 is a mechanism-specific biomarker of caspase-driven cell death. Multiple additional liver disease biomarkers achieved statistically significant reductions vs. placebo in the overall patient population after three months
This program is evaluating vadadustat (formerly AKB-6548) in non-dialysis patients with anemia related to chronic kidney disease (NDD-CKD). In addition, the U.S. Food and Drug Administration (FDA) recently
Furthermore, high diversity among CTCs was not associated with resistance to taxane-based chemotherapy. This suggests that patients likely to fail anti-androgen therapies but potentially benefit from chemotherapy can
Matinas BioPharma president and CEO Roelof Rongen said: "In preclinical studies, MAT2501 was shown to have oral bioavailability and provide targeted delivery of the powerful antibiotic, amikacin, directly
Validation confirms that the submission is complete and initiates the Centralized Review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). Under Centralized Review, the
Under the terms of the agreement, Merus and Gustave Roussy will collaborate on the design and conduct of basic, preclinical and translational research studies and early clinical studies
PIKA rabies vaccine is an innovative rabies vaccine independently developed by Yisheng Biopharma, using a novel double-strand RNA analog ("PIKA") which acts as a toll-like receptor-3 (TLR-3) agonist